Balziva Kit
NDC Package 0555-9034-58

11-digit billing NDC: 00555903458 · Billing unit: EA · 6 EA per package

Package Information

Balziva (norethindrone and ethinyl estradiol) kits is oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.Oral contraceptives are highly effective. This formulation utilizes a kit delivery system. Marketed by Teva Pharmaceuticals Usa, Inc., this product is identified by NDC 0555-9034 and is authorized under FDA application ANDA076238.

Identification & Billing

NDC Package Code
0555-9034-58
Package Description
6 POUCH in 1 CARTON / 1 BLISTER PACK in 1 POUCH (0555-9034-79) / 1 KIT in 1 BLISTER PACK
Product Code
11-Digit Billing Format
00555903458
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
6 EA
RxNorm Crosswalk
  • RxCUI: 1095362 - {21 (ethinyl estradiol 0.035 MG / norethindrone 0.4 MG Oral Tablet) / 7 (inert ingredients 1 MG Oral Tablet) } Pack [Balziva 28 Day]
  • RxCUI: 1095362 - Balziva 28 Day Pack
  • RxCUI: 238015 - norethindrone 0.4 MG / ethinyl estradiol 0.035 MG Oral Tablet
  • RxCUI: 238015 - ethinyl estradiol 0.035 MG / norethindrone 0.4 MG Oral Tablet
  • RxCUI: 748797 - inert 1 MG Oral Tablet

Clinical Specifications

Proprietary Name
Balziva
Non-Proprietary Name
Norethindrone And Ethinyl Estradiol
Dosage Form
Kit - A packaged collection of related material.
Usage Information
Oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.TABLE 1: LOWEST EXPECTED AND TYPICAL FAILURE RATES DURING THE FIRST YEAR OF CONTINUOUS USE OF A METHOD % of Women Experiencing an Accidental Pregnancy in the First Year of Continuous Use MethodLowestExpectedaTypicalb(No contraception)(85)(85)Oral contraceptives combined0.13c progestin only0.53cDiaphragm with spermicidal cream or jelly618Spermicides alone (foam, creams, jellies and vaginal suppositories)321Vaginal sponge nulliparous618 multiparous928IUD0.8 to 23dCondom without spermicides212Periodic abstinence (all methods)1 to 920Injectable progestogen0.3 to 0.40.3 to 0.4Implants 6 capsules0.040.04 2 rods0.030.03Female sterilization0.20.4Male sterilization0.10.15Reproduced with permission of the Population Council from J. Trussell, et. al: Contraceptive failure in the United States: An update. Studies in Family Planning, 21(1), January-February 1990.a) The authors’ best guess of the percentage of women expected to experience an accidental pregnancy among couples who initiate a method (not necessarily for the first time) and who use it consistently and correctly during the first year if they do not stop for any reason other than pregnancy.b) This term represents “typical” couples who initiate use of a method (not necessarily for the first time), who experience an accidental pregnancy during the first year if they do not stop use for any reason other than pregnancy.c) Combined typical rate for both combined and progestin only.d) Combined typical rate for both medicated and nonmedicated IUD.

Regulatory & Marketing

Labeler Name
Teva Pharmaceuticals Usa, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA076238
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
10-16-2006
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0555-9034-58 identifies a specific commercial package of 6 pouch in 1 carton / 1 blister pack in 1 pouch (0555-9034-79) / 1 kit in 1 blister pack of Balziva, a human prescription drug labeled by Teva Pharmaceuticals Usa, Inc.. This kit is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Teva Pharmaceuticals Usa, Inc. on October 16, 2006. The current certification is valid through December 31, 2026.

How is this Teva Pharmaceuticals Usa, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00555903458. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 6 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0555-9034-58
11-Digit CMS (5-4-2)
00555-9034-58

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.